A human monoclonal antibody inhibiting partially factor VIII activity reduces thrombus growth in baboons

Background: The inhibitory activity of an anti‐factor VIII (FVIII) antibody can be modulated through glycosylation of the antigen binding site, as has recently been described. This offers the opportunity to develop an optimized anticoagulant agent targeting partial FVIII inhibition. Objectives: We investigated in non‐human primates the antithrombotic activity, pharmacokinetics,and pharmacodynamics of a human monoclonal antibody, Mab‐LE2E9Q, inhibiting FVIII activity partially. Methods: The ability of Mab‐LE2E9Q to prevent thrombosis was evaluated in baboons after administration of 1.25 and 5 mg kg−1 antibody or saline as a single intravenous (i.v.) bolus. Thrombus development was recorded in expansion (‘venous’) and in Dacron® (‘arterial’) thrombosis chambers incorporated in an extracorporeal arteriovenous shunt implanted between the femoral vessels 1 h, 24 h and 7 days after the administration of Mab‐LE2E9Q. Results: Mab‐LE2E9Q reduced thrombus growth to a similar extend 1 h, 1 day and 1 week after administration of the antibody. Ex vivo pharmacodynamic analysis indicated that the evaluation of the residual FVIII activity was strongly dependent on the type of FVIII assay and on the phospholipid concentration in the assay. No significant difference in bleedings was observed between animals treated with Mab‐LE2E9Q or with saline. Conclusions: Understanding the role of glycosylation in FVIII inhibition by a human monoclonal antibody allowed selection of an antibody inhibiting only moderately FVIII activity while significantly reducing thrombus development in a baboon extracorporeal model. As that antibody did not increase the bleeding tendency, it may represent a novel type of a long‐acting antithrombotic agent with an optimal safety/efficacy profile.